NBIX: Elagolix is antagonist not agonist. They work differently. A longer Phase 3 is expected; but still we are talking about a big market with not much competition.
EV of NBIX of only 100millions, very cheap for a company with a phase 3-ready drug and a few phase 1/2 programs going.
Market Data 
Markets 
AI
